HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The therapeutic efficacy of α-pinene in an experimental mouse model of allergic rhinitis.

Abstract
In the present study, the therapeutic effect and underlying mechanism of α-pinene (α-PN) in the ovalbumin (OVA)-sensitized allergic rhinitis (AR) model were investigated. Our results showed that pretreatment with α-PN caused a decrease in clinical symptoms, including a decrease in the number of nasal, eye, and ear rubs, and spleen weight in the OVA-sensitized mice. The level of interleukin (IL)-4 was decreased on the spleen tissue of α-PN treated mice. Pretreatment with α-PN significantly decreased levels of nasal immunoglobulin E. Protein levels of tumor necrosis factor-α, intercellular adhesion molecule-1, and macrophage inflammatory protein-2 were decreased by the administration of α-PN in the nasal mucosa of the OVA-sensitized mice. The increased numbers of eosinophils and mast cells infiltrating the nasal mucosal tissue of mice with AR were decreased following oral administration of α-PN. Post-treatment with α-PN 1h after OVA challenge also resulted in a significant reduction of clinical symptoms and IgE levels. In addition, the expression and phosphorylation of receptor-interacting protein 2 (RIP2) and IκB kinase (IKK)-β and activation of nuclear factor-κB (NF-κB), and caspase-1 were all increased in the activated human mast cell line, HMC-1 cells, however, increased activations of RIP2, IKK-β, NF-κB, and caspase-1 were inhibited by treatment with α-PN. Taken together, we suggest that α-PN is a promising anti-allergic agent and may be useful in the clinical management of AR.
AuthorsSun-Young Nam, Cha-kwon Chung, Jun-Ho Seo, So-Young Rah, Hyung-Min Kim, Hyun-Ja Jeong
JournalInternational immunopharmacology (Int Immunopharmacol) Vol. 23 Issue 1 Pg. 273-82 (Nov 2014) ISSN: 1878-1705 [Electronic] Netherlands
PMID25242385 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier B.V. All rights reserved.
Chemical References
  • Anti-Allergic Agents
  • Bicyclic Monoterpenes
  • Chemokine CXCL2
  • Cxcl2 protein, mouse
  • Icam1 protein, mouse
  • Monoterpenes
  • NF-kappa B
  • Tumor Necrosis Factor-alpha
  • Intercellular Adhesion Molecule-1
  • Interleukin-4
  • Immunoglobulin E
  • RIPK2 protein, human
  • Receptor-Interacting Protein Serine-Threonine Kinase 2
  • I-kappa B Kinase
  • Caspase 1
  • alpha-pinene
Topics
  • Animals
  • Anti-Allergic Agents (therapeutic use)
  • Bicyclic Monoterpenes
  • Caspase 1 (metabolism)
  • Cell Line
  • Cell Movement (drug effects)
  • Chemokine CXCL2 (genetics, metabolism)
  • Disease Models, Animal
  • Eosinophils (drug effects, immunology)
  • Female
  • Gene Expression Regulation (drug effects)
  • Humans
  • I-kappa B Kinase (metabolism)
  • Immunoglobulin E (metabolism)
  • Intercellular Adhesion Molecule-1 (genetics, metabolism)
  • Interleukin-4 (metabolism)
  • Mast Cells (drug effects, immunology)
  • Mice, Inbred BALB C
  • Monoterpenes (therapeutic use)
  • NF-kappa B (metabolism)
  • Nasal Mucosa (drug effects, immunology)
  • Receptor-Interacting Protein Serine-Threonine Kinase 2 (metabolism)
  • Rhinitis, Allergic (drug therapy)
  • Signal Transduction (drug effects)
  • Tumor Necrosis Factor-alpha (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: